Treatment of Opioid Dependence and Coinfection with HIV and Hepatitis C Virus in Opioid- Dependent Patients: The Importance of Drug Interactions between Opioids and Antiretroviral Agents

The occurrence of human immunodeficiency virus (HIV) disease and hepatitis C is common in injection drug users, most of whom are opioid dependent. Methadone pharmacotherapy has been the most widely used treatment for opioid addiction in this population. Methadone has significant, adverse drug-drug i...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2005-07, Vol.41 (Supplement-1), p.S89-S95
Main Author: Elinore F. Mc Cance-Katz
Format: Article
Language:English
Subjects:
AIDS
Anti-Retroviral Agents - pharmacokinetics
Anti-Retroviral Agents - pharmacology
Antiretroviral drugs
Antiretroviral Therapy, Highly Active
Antiretrovirals
Buprenorphine - pharmacokinetics
Buprenorphine - pharmacology
Clinical outcomes
Dosage
Drug dependence
Drug Evaluation - trends
Drug Interactions
Drug therapy
Hepatitis
Hepatitis C - complications
Hepatitis C - drug therapy
Hepatitis C virus
Highly active antiretroviral therapy
HIV
HIV Infections - complications
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Methadone
Methadone - pharmacokinetics
Methadone - pharmacology
Narcotics - pharmacokinetics
Narcotics - pharmacology
Opioid analgesics
Pharmacokinetics
Protease Inhibitors - pharmacokinetics
Substance Abuse, Intravenous - complications
Substance Abuse, Intravenous - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The occurrence of human immunodeficiency virus (HIV) disease and hepatitis C is common in injection drug users, most of whom are opioid dependent. Methadone pharmacotherapy has been the most widely used treatment for opioid addiction in this population. Methadone has significant, adverse drug-drug interactions with many antiretroviral therapeutic agents that can contribute to nonadherence and poor clinical outcomes in this high-risk population. The present article summarizes current knowledge about interactions between methadone and antiretroviral medications. Buprenorphine is the newest agent available for the treatment of opioid dependence and may have fewer adverse interactions with antiretroviral agents. Buprenorphine has a significant pharmacokinetic interaction with efavirenz but no pharmacodynamic interaction; therefore, simultaneous administration of these drugs is not associated with opioid withdrawal, as has been observed with methadone. This promising finding may simplify the treatment of opioid-dependent patients with HIV disease and should also improve clinical outcomes for persons coinfected with HIV and hepatitis C virus.
ISSN:1058-4838
1537-6591
DOI:10.1086/429503